Compugen Announces Extension of Collaboration With Pfizer.Business Editors & Health/Medical Writers BIOWIRE2K TEL AVIV Tel Aviv (tĕl əvēv`), city (1994 pop. 355,200), W central Israel, on the Mediterranean Sea. Oficially named Tel Aviv–Jaffa, it is Israel's commercial, financial, communications, and cultural center and the core of its largest , Israel--(BW HealthWire)--July 22, 2002 New Agreement Includes the Licensing of Compugen's LEADS Platform and Z4000 and Z3 Software Packages for Proteomic Research Compugen Ltd. (Nasdaq:CGEN CGEN Convective Sigmet Generation ) announced today an extension of its collaboration with Pfizer Global Research and Development. This collaboration began in late 1998 with the Parke-Davis division of Warner-Lambert Company. The continuation agreement provides Pfizer with LEADS, Compugen's computational biology Not to be confused with Biologically-inspired computing. Computational biology is an interdisciplinary field that applies the techniques of computer science, applied mathematics, and statistics to address problems inspired by biology. platform for drug discovery, and Z4000 and Z3, 2D gel analysis software packages for advanced proteomic analysis. Financial terms of the new agreement were not disclosed. "Compugen's research collaborations with leading pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. such as Pfizer, Novartis and Millennium are an important component of our industry-leading computational biology efforts," stated Erez Chimovits, Compugen's Executive Vice President, Marketing and Sales. "This extension of our partnership with Pfizer is further evidence of the growing recognition of the inherent value provided by our products and technologies." About the Products LEADS Compugen's LEADS platform, an experimentally verified system, is used to accelerate the development of therapeutic and diagnostic products by creating a comprehensive view of the transcriptome The transcriptome is the set of all messenger RNA (mRNA) molecules, or "transcripts", produced in one or a population of cells. The term can be applied to the total set of transcripts in a given organism, or to the specific subset of transcripts present in a particular cell type. , the biological bridge between the genome and the proteome pro·te·ome n. The complete set of proteins that are produced by the genes of an organism. proteome the entire complement of proteins produced by a cell. , through modeling of complex biological phenomena such as alternative splicing Alternative splicing is the RNA splicing variation mechanism in which the exons of the primary gene transcript, the pre-mRNA, are separated and reconnected so as to produce alternative ribonucleotide arrangements. . Z4000 Z4000 is a fully automated system for accurately designing, analyzing, and controlling large-scale experiments of proteins as they appear on 2D gels. The system marks a significant breakthrough in the management and image analysis of multidimensional gel collections. Z3 Z3 is a high throughput image analysis system for comparative analysis of images of proteins separated on 2D gels. Z3 technology employs advanced proprietary image analysis algorithms that substantially enhance the accuracy, increase the throughput and automate the analysis process of 2D gel images. About Compugen Compugen (Nasdaq:CGEN) is a pioneer in the merging of computational technologies with biology, chemistry and medicine to enhance drug discovery and development. This unique capability is a proven basis for providing high value products and services to leading biotechnology and pharmaceutical companies and for in-house therapeutic and diagnostic discovery. For additional information, please visit Compugen's corporate Website at www.cgen.com and the Company's Internet research This article is about using the Internet for research; for the field of research about the Internet, see Internet studies. Internet research is the practice of using the Internet, especially the World Wide Web, for research. engine for molecular biologists, www.LabOnWeb.com. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements include words like "may," "expects," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the development of new products; the ability to implement technological improvements; the ability of Compugen to obtain and retain customers. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's Registration Statement on Form F-1 and its annual reports filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion